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CANCER BIOMARKERS, AND NOVEL TECHNIQUES FOR DETECTION 
  
  
TAMEEM JAMAL 
  
  
  
ABSTRACT  
Technologies for early detection of tumors is critical for better therapy outcome 
and overall change in cancer survival.  These assays must be capable of 
detecting tumors at early stages in order to prevent metastasis of the tumor and 
help reduce mortality. Biological molecules can serve as markers that can 
indicate the presence of cancerous cells. Current biomarkers approved by the 
FDA include CA 125, which is a tumor associated antigen (TAA). However, the 
sensitivities of these TAAs is not high enough to detect at early stages of 
disease. Recent technologies have found that antibodies that recognize these 
TAAs, also known as autoantibodies, provide more sensitive means to screen for 
tumors. This review aims to present recent literature data relative to the field of 
cancer diagnosis and treatment. However, one should note that this article 
covers only fraction of the broad science behind this subject. 
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Introduction 
 
Cancer has presented to be a persisting global predicament that burdens 
humanity with the deaths it causes. In 2010 there has been over 3.7 million 
cancer deaths registered in over 60 countries [1]. The battle against cancer 
persists with a slight increase in the 5-year survival percentage for patients with 
some cancers [2]. However, lung and liver cancer remain lethal in both 
developing and developed countries, and more specifically lung cancer mortality 
for women has risen in most Latin American countries by 1-3% [2-3]. More 
findings have displayed that children with acute lymphoblastic leukemia had a 
much variable 5-year survival rate globally, with 60% in some countries and 90% 
and above in Canada and four other European countries indicating the absence 
of the appropriate treatment for children with cancer in certain regions of the 
world [4]. By 2010 there was a 38% increase in cancer deaths and projections 
are indicating that this problem will persist. Predictions are that by 2030, 20 
million people will be diagnosed with cancer every year, and will have more than 
13 million cancer deaths, with most of these deaths being in developing 
countries. These projections are based on population growth and aging of the 
population [4-5]. 
   The threat that cancer poses to lives is continuously growing. In order to 
address the issue successful strategies for screening, early diagnosis, prognosis, 
and risk stratification are needed to decrease mortality and increase the 
probability of curing the dis-ease. However, not all cancers can be detected at 
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such an early stage. This can be illustrated in the case of breast cancer, which is 
the most common invasive cancer in females [6-7]. A mammography is 
considered to be the gold standard of breast cancer screening and remains the 
only screening test proven to re-duce mortality, but not all cancers can be 
visualized on screening mammograms. Mammographic sensitivity decreases 
significantly as breast density increases, with sensitivity reported to be as low as 
45% in women with extremely dense breasts. On the other hand, mammograms 
can also lead to over diagnosis, which can be tumors that might not require 
intervention, and cause unnecessary treatments for some patients. Other issues 
with mammography screenings include radiologist assessment, patient age, 
breast density, malpractice concerns, and quality control procedures. Full-field 
digital mammography and computer-aided detection programs have been 
proposed, but the results from these techniques remain controversial. Magnetic 
resonance imaging (MRI) has proven to be able to detect small tumors that 
mammography and ultrasounds cannot. However, MRIs lack sufficient specificity 
and cost-effectiveness to be used as a general screening tool [7]. Other 
screening methods for other cancers such as colonoscopy for colon cancer, 
computed tomography for lung cancer, prostate-specific antigen for prostate 
cancer, and Papanicolaou stains for cervical cancer also face similar limitations 
such as in terms of sensitivity, specificity, complexity, cost, and compliance [8]. 
   In order to make early detection an effective and practical approach, screening 
tests must satisfy a set of rudimentary requirements. First, screening tests should 
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be able to distinguish between healthy individuals and cancer cases with a high 
degree of accuracy, sensitivity, and specificity. Hence, low false-negative and 
false-positive rates. Second, detection should be possible at early stages before 
the disease progresses to an advanced stage, or even before the first 
manifestation of clinical signs, when it is still curable. Third, the test should ideally 
allow discrimination between lesions that are aggressive and require treatment 
and those that ultimately will do no harm, thus reducing the problem of over 
diagnosis. Fourth, tests should be inexpensive and well accepted by the target 
population [7]. 
 Advances in the field of genomics and related computational tools are constantly 
occurring and applied in cancer-related research. Yet, with all its potential 
genomics still requires other fields to complement its limitations. Proteomics, the 
large scale study of the function and structures of proteins, provides a vast field 
of technologies and techniques that can further advance cancer studies. Using 
proteomics in studying diseases is considered to be a dynamic and innovative 
approach that could confirm, complement, or provide more elaborate information 
beyond that obtained by other methods. Even though several genes were 
identified by genomics technologies to be specifically related to cancers, the 
function of such genes and the data interpretation in the context of functional 
networks require the power of proteomics. Proteins are highly dynamic molecules 
that can be subjected to extensive functional regulation by various processes 
such as proteolytic degradation, post-translational modification, involvement in 
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complex structures, and compartmentalization. Therefore, in-depth studying of 
proteomics profiles of various specimens obtained from cancer patients can 
enhance researchers’ comprehension of tumor pathogenesis, monitoring, and 
the identification of novel targets for cancer therapy. Furthermore, an essential 
goal for applying proteomics to study cancers is to utilize its methods in clinical 
laboratories for the purpose of diagnostic and prognostic categorization of 
cancers [9]. 
Detection of cancers at an early stage, provides more opportunities for treatment. 
However, early detection is a current challenge that the scientific and medical 
communities face. For most clinical blood biomarkers lack the sensitivity and 
specificity necessary.  Recent advances in the field of diagnostic assays for 
cancer detection has led to the identification of various mechanisms, which 
cancer cells provide molecular markers that allow for their detection. These 
biomarkers include autologous cellular components called tumor associated 
antigens (TAA) also known as cancer associated proteins (CAPs). Most of the 
FDA (Food & Drug Administration) approved blood based assays for evaluating 
the disease state in cancer patients rely on the determination of the serum levels 
to those TAAs. Recent studies, focusing on ovarian cancer, have developed a 
mathematical model looking at the estimated time at which ovarian cancer can 
be detected by using an assay that measures the amount of the TAA cancer 
antigen 125 (CA 125). Shockingly and regardless of the reported sensitivity of CA 
125 measuring assay, the study indicated that a tumor could grow unnoticed for 
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more than 10 years growing to a size more than 2.5 centimeters before 
becoming detectable. Furthermore, this model may be extended to other tumors 
using the correct assumptions [9-11].  
 
 
Figure 1 Cancerous TAAs: Cancerous cell that contains TAAs that are either 
expressed on the cell membrane or secreted into the extracellular space, which 
can then trigger a humoral immune response using AAbs [7]. 
The search for better biomarkers for detecting cancer continues. One direction 
that holds promise in predicting the presence of cancer is understanding the 
complexity tumor specific proteome by identifying the immune responses 
generated against these TAAs. The immune system is capable of sensing 
aberrant expression of certain cellular components involved in tumorigenesis and 
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the product autoantibody response provides an insight to the targets that are 
responsible for eliciting immunogenicity to these cellular components. Cancer 
associated autoantibodies (AAbs) are currently considered as excellent 
candidates for cancer biomarkers (Figure 1). For they represent biosensors that 
the immune system provides, as a result of its response to a developing tumor. 
Also, the production of these AAbs in response to these TAAs would not be 
static, but would be present as measurable physiological changes that one could 
relate to the disease state. Immunoglobulins (Igs) are extremely stable in serum 
samples and are known to persist for extended times after the removal of  its 
antigenic factor. This provides an advantage for the usage of AAbs over other 
potential markers in body fluids which are usually comprised of either proteins or 
polynucleotides. These classes of molecules once released by tumors are known 
to be quickly degraded and/or removed from circulation after a related short 
duration of time. The lack of long-term stability of non-immunoglobulin associated 
tumor markers in samples is a significant technical barrier to their implementation 
as biomarkers because of a limit half-life in serum and therefore their limited 
window of detectability. Therefore, tumor AAbs provide a promising potential as a 
biomarker for cancers that can be used for early detection and for providing 
diagnostic information for the status of the tumor [11].   
   The purpose of this article is to present the reader with some of the techniques 
and technologies used in early detection assays for cancer. As this review serves 
to update those familiar in this field and introduce these concepts to those new to 
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it. However, this review only covers a portion of the vast field that it attempts to 
describe.  
 
 
Figure 2 Tumor Immunoblots Average number of spots detected using the 2D 
immunoblots during the first five weeks of tumor growth in female and male mice 
for both IgM (a) and IgG (b) [13]. 
IgM a new potential AAb 
As mentioned earlier AAbs can serve as a method for detecting cancer cells. 
Breast cancer being the most common cancer in women worldwide has an 
enormous demand for finding an accurate yet cost effective assay. Most studies 
on breast cancer have focused on the development of IgG-like molecules as 
biomarkers or as a treatment for the advanced stages of cancer, but AAbs IgM 
against TAAs have not been examined as early diagnostic tools for breast 
cancer. IgM is the first line of defense of an organism. In its secreted form, IgM is 
a pentamer that comprises 5 4-chain antibodies, giving it a total of 10 antigen 
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(Ag) binding sites and thus higher valency and avidity than the structures of other 
immunoglobulins. Each pentamer contains one copy of another polypeptide 
chain, called a J (joining) chain. IgM regulates B cell development, facilitates the 
clearance of apoptotic cells, modulates inflammatory responses and autoimmune 
diseases and mediates the elimination of cancer cells. There are two types of 
IgM that exists natural and adaptive [12-13] 
 Natural antibodies (Abs) are present in an organism without any antigenic 
exposure. Most natural Abs are predominantly IgM. Natural IgM Abs are germline 
encoded and not affinity matured. Natural IgM has a significant function in 
primary defense mechanisms. They participate in the early recognition and 
elimination of bacterial and viral invaders and altered self-material from an 
organism, reacting with cell surface receptors and recognizing and removing 
apoptotic and senescent cells, cell debris and self-Ags. Natural IgM is associated 
with the recognition and removal of precancerous and cancerous cells. Natural 
IgM binds preferentially to post-transcriptionally modified cell surface Ags that are 
tumor-specific, recognizing the conserved structures of carbohydrate epitopes. 
Carbohydrate epitopes that are recognized by natural IgM are stably expressed 
in many tumors at various precursor stages. Unlike epitope-based single-peptide 
chains, glycoepitopes share structural homologies beyond the limits of the 
protein families; thus, they can crossreact and constitute the preferred targets for 
natural IgM Ab [12-13].  
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On the other hand, adaptive IgM appear after the introduction of an antigen, in 
fact they are the first antibody to appear after an immunological challenge. Its 
production normally decreases as IgG response begins to develop. Hence, IgM 
is not considered to have a significant role in long term immunity, even though it 
does protect the host effectively. The adaptive immune response requires at 
least 1 week to generate monospecific high-affinity Abs, first producing IgM 
followed by isotype-switching to IgG [12-13]. 
Natural and adaptive IgM levels are constant from transformation until the tumor 
is established. On the other hand, IgG is present only in the initial stages of 
adaptive immunity, it becomes immunosuppressed when the breast tumor is 
formed. These IgM also participate in recruiting Ags into secondary lymphoid 
organs, priming subsequent adaptive immune response. IgM reactivity against 
TAAs can be measured as an early sign of breast cancer in vivo and detect the 
disease earlier than current methods; further-more, natural IgM is detected in the 
asymptomatic stages of cancer, up to 5 years before disease onset. A recent 
study injected tumor 4 T1 cell antigens into mice and the IgM and IgG responses 
were measured using 2D immunoblotting. The studies finding indicated a 
decreased amount of IgG over time, hence, indicating IgG immunosuppression 
as the tumor develops. Meanwhile the IgM in the female mice did not decrease 
indicating that no IgM immunosuppression occurred during tumor growth. More 
results indicated no immunosuppression of either IgG or IgM in male mice, which 
can be explained by the fact that the 4 T1 cell antigens were of female origin, 
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hence the male mice immune system raised a response against the 4 T1 cell 
antigens (Figure2). One of the discovered IgM AAbs includes natural IgM SC-1. 
SC-1 binds to a tumor-specific carbohydrate epitope of decay acceleration factor-
B (DAF), which is specifically expressed in the membrane of stomach carcinoma  
cells, and induces apoptosis [12-13].  
 
Figure 3 Immunofluorescence Staining and AAb Detection (A) Immunofluorescence 
staining of HepG2 and MCF-7 cells with K94 antibody, anti CK18 and anti CK8, (B) 
Detection of autoantibody against CK8/CK18 complexes in breast cancer (BC) patients' 
sera and healthy individuals’ sera (Nor) by K94p1 mimotope ELISA [14]. 
Mimitopes a different approach for immunoassays 
As previously discussed different components of body fluids are ideal biomarkers 
for disease diagnosis, because of their simplicity of detection. Serum has long 
been considered as a rich source for biomarkers and a large number of serum 
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cancer biomarkers have been proposed (CA 15.3). Unlike the traditional tumor 
markers, serum AAbs to TAAs are detectable even when the tumor is very small, 
which makes them potential biomarkers for early cancer diagnosis. Moreover, the 
advantages of simple assays that detect AAbs in sera uses target antigen and 
secondary reagents, in contrast to serum protein markers whose detection needs 
two different monoclonal Abs, thus, making it easy to devise a multiplex tumor-
associated autoantibody assay. Two techniques that have been previously used 
to identify many tumor associated AAbs are the serological identification of 
antigens by recombinant DNA expression (SEREX) and serological proteome 
analysis (SEPRA).  Yet, these techniques give bias results that are more 
favorable for the more abundant AAbs [14]. In order to determine the amount of 
AAbs in the serum one would typically use an enzyme linked immuno-sorbent 
assay (ELISSA). These assays require the antigen in order to detect the AAbs. 
These antigens can be produced in a recombinant system. However, some 
proteins are difficult to produce and purify. A novel approach to access this 
problem was to create mimotopes that are usually peptide sequences that 
contain the unique antigenic determinant specific for the AAbs [14-15]. 
   A study found tumor associated AAbs that reacted against fatty acid synthase 
(FASN). These anti-FASN Abs were measured using a mimotope of FASN. The 
same study also led to the discovery of another AAbs, K94. K94 is an anti-
cytokeratin (CK) 8/18 complex antibody. An immunofluorescence staining of 
HepG2 and MCF-7 cancer cells alongside with other data suggested that K94 Ab 
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recognizes an epitope presented by complexing of CK8 and CK18 (Figure 3A). 
As it seemed that K94 Abs stained the membrane of the cell, which is where 
previous reports have indicated the distribution of the CK8/18 complex. In order 
to measure the amount of K94 in the serum a mimotope that contained the same 
CK8/CK18 Ag that is recognized by K94 was devised. This mimotope was used 
in a phage ELISSA and had a sensitivity of 50% and a specificity of 82.61% 
(Figure 3B). This mimotope ELISA, was not very sensitive, but was more useful 
than the CA 15.3 assay, which is the FDA approved TAA for cancer diagnostics 
[14-16].  
   Another notable AAbs is IMAB362, also known as anti-Claudin 18.2, targets 
cancer specific cell surface target Claudin 18 isoform 2, which is a 27.7 kDa 
gastric differentiation protein that spans the cell membrane with four 
transmembrane helices. In an ongoing randomized Phase IIb trial, IMAB362 is 
being combined with standard chemotherapy for first-line treatment of 
gastroesophageal cancer. In the progress of developing IMAB362 for clinical use, 
the detection and quantification of the antibody after application to animals and 
patients is essential for the characterization of absorption, distribution, 
metabolism, excretion, and pharmacokinetic properties. Typically, ELISSA based 
assays are being applied for this purpose using the corresponding antigen. 
Unfortunately, as mentioned earlier not all proteins can be produced easily  
including transmembrane proteins handle due to their nature as membrane-
embedded structure. This obstacle can be overcome by generating mimotopes. 
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The best mimotope (apparent KD = 0.15 nM) was successfully generated by 
testing different sequences of peptides recognized by the AAb, and was then 
used for the ELISA-based quantification of IMAB362 in samples from a mouse 
pharmacokinetic study [17].  
 
Figure 4 The effect of MAb 2B2 on the two cancer cell strains HT 29 & SW260.  
(A) Measured cell growth by sulforhodamine B assay after being incubated with variable 
concentrations of MAb 2B2 and the control UPC10, (B) Per-cent cell death measured 
using the Trypan blue exclusion test after being incubated with variable concentrations 
of MAb 2B2 and the control UPC10, (C) In situ detection of cell apoptosis in the two cell 
A 
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lines using MAb 2B2 (20 μg/ml), UPC10 (20 μg/ml) as a negative control and stauro-
sporine 20 (μM) as a positive control [18]. 
AAbs for screening and treating CRC 
Even though most studies have directed their attention in modifying assays to 
increase efficiency and accuracy of their assays some continue to search for 
more viable biomarkers. A recent study focuses on TAAs found in colorectal 
cancer (CRC). CRC is the most common form of cancer among those that affect 
the gastrointestinal tract and represents the third most frequent cancer in men 
and the second in women. The ribosomal P proteins are studied and compared 
to other TAAs. Ribosomal P proteins are involved in the formation of the 
ribosomal stalk of the 60 S ribosomal subunit in eukaryotic cell, in which they 
regulate protein synthesis. The immunogenicity of the ribosomal P0 protein was 
previously demonstrated in breast and prostate cancer patients. The 
immunodominant C-22 P0 epitope was found to be located within the 22 amino 
acid C-terminal peptide shared by all three P proteins. P0 exists as a free protein 
in the cytoplasm and on the surface of cancer cells and appears to promote 
tumor formation. The humoral immune response to ribosomal P proteins, 
carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR) and 
human epidermal growth factor receptor 2 (ErbB2 or HER2) in CRC patients with 
the expression of the C-22 P0 epitope in colon cancer tissues was investigated. 
Also the C-22 P0 epitope expression in two colon adenocarcinoma cell lines was 
studied along with the in vitro effect of a monoclonal antibody (MAb 2B2) which 
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recognizes this epitope on the growth of colon cancer cells. It was found that 
none of the sera from healthy donors displayed reactivity to P proteins. 
Conversely, 7 out of 67 sera from CRC patients reacted to ribosomal P proteins. 
The prevalence of anti-P proteins AAbs in CRC patients was significant 
compared to that of healthy donors (p = 0.0048). The antibody response to anti-P 
proteins was not associated with the stage of disease. Patients with anti-P 
proteins antibodies showed either at early or an advanced stage of disease. 
Meanwhile, none of the patients’ sera should any reactivity towards CEA and 
only two patients displayed a response towards EGFR and one for ErbB2. 
Further-more, MAb 2B2 significantly inhibited cell growth (in vitro) in the two CRC 
cell lines HT29 and SW260 in a dose dependent manner compared to the control 
antibody UPC10 (Figure 04). When used at higher concentration (20 μg/ml), MAb 
2B2 decreased cell growth of 45% in SW260 cells and 30% in HT29 cells [18-
19]. 
Other notable molecules and techniques 
In relationship to cancer AAbs, other studies have been directed in studying 
AAbs related to diseases in general, such as auto immune diseases. One tool 
that has been devised is the Autoantibody Profiling System – 90 (APS -90). APS-
90 is based according to the literature, 90 of the wells contain probes (antigens) 
against proteins relevant in autoimmune diseases, 4 wells contain standards for 
generation of a standard curve and 2 wells contain probes for positive and 
negative controls. The 90 probes target autoantibodies that are reported to be 
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present in several diseases including cancer, lupus, chronic obstructive 
pulmonary disease (COPD), cardiovascular disease, autism, diabetes, 
rheumatoid arthritis and inflammatory bowel syndrome which makes the kit ideal 
for discovery and verification of the presence or absence of autoantibodies. The 
workflow process for APS-90 is similar to that of ELISA, and the APS-90 kit 
includes reagents in a ready-to-use format which enhances consistency. the 
APS-90 detected 29 autoantibodies in the human plasma samples that were 
analyzed, all of which are relevant in autoimmune disorders. Among them, 4 
AAbs were present at significantly different levels between the test (ovarian 
cancer) and control (no cancer) groups [20]. This novel technique has yet to be 
explored for further applications. 
   Other AAbs for biomarkers include AAbs against lectin galactoside-binding 
soluble 3 binding protein (LGALS3BP). LGALS3BP, also known as 90K or-Mac-2 
BP, has been largely regarded as a TAA, since it is present at elevated 
concentrations in the blood of cancer patients and is overexpressed in the vast 
majority of cancer tissues. Anti-LGALS3BP was screened for using an ELISA. It 
was found that the Anti-LGAL3BP screening had a sensitivity of 33% (26/71 
patients were positive) and a specificity of 98% (only one of the 54 controls gave 
a false positive) [8]. These findings further support the potential of AAbs in early 
screening for cancer.  
As most studies have been searching for reliable AAbs to use in screening, 
others have been searching within a broader spectrum of biomarkers including 
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various TAAs and cancer related biomolecules. A study focusing on Estrogen 
receptor (ER) positive/progesterone receptor (PR)-positive invasive ductal 
carcinoma, which accounts for ~45 % of invasive breast cancer (BC) diagnoses 
in the U.S, performed a broad study in identifying potential markers. The re-
searchers utilized an antibody array platform in order to detect these markers. 
The screening arrays included >3000 antibodies directed against >2000 proteins, 
which encompass many cytokines, adipokines, growth factors, and other 
secreted or membrane proteins implicated in a range of biological pathways 
dysregulated in BC. Four potential markers were found and identified as Colony 
stimulating factor 2 (CSF2), transferrin receptor (TFRC), RING1 and YY1 binding 
protein (RYBP), and integrin b4 (ITGB4). However, one would note that 
compared to AAbs these markers have lower specificity and sensitivity [21-23]. 
 Nevertheless, there are multiple other assays that may not be designed for 
detecting cancer biomarkers but have the potential to do so. One of these 
technologies include microchips sensors known as lab on a chip (LOC). These 
LOC are capable of detecting certain molecules efficiently [24]. Another recently 
developed technology is the luciferase immunoprecipitation systems (LIPS). LIPS 
relies on luciferase (Ruc), which is expressed in mammalian cells in a form that is 
fused to the protein that binds the desired Ab. A mixture of Ab is added to the 
Ruc-Ag solution and Ab bound to this protein can be selected by various 
methods, while unbound Ag can be washed away, and the amount of bound Ab 
can be measured by the light produced from the Ruc enzyme. LIPS and other 
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assays, along with clinical information including association with family members 
and the presence of risk genes, could be efficiently used to identify individuals at 
high risk for developing these and other conditions including cancer [25]. 
Cell free produced Ag for AAb detection. 
As mentioned earlier, the detection of antibodies in sera has broad applications 
for detection and monitoring of infectious diseases, autoimmunity, and cancer. 
Proteomic methods of antigen detection, such as protein microarrays, serve as 
excellent clinical discovery tools, but both cost and specialization of manufacture, 
set limits to this assay. Downstream assays for biomarker validation studies 
require rapid, reproducible, multiplexed assays for the simultaneous screening of 
fewer (<100) antigens with hundreds or thou-sands of sera. Traditional clinical 
ELISA assays use recombinant proteins, but these are limited by the ability to 
purify proteins free of cross-reacting contaminants and are limited to one antigen 
at a time [26]. 
   A novel method in screening for AAbs utilizes techniques to express proteins 
outside of cell outside of living cells by subjecting gene DNA to ‘cell-free’ in vitro 
coupled transcription and translation (IVTT) reagent. This is the process used for 
nucleic acid programmable protein arrays (NAPPA) to express unique proteins 
from plasmid DNA containing their full-length genes. Proteins are expressed and 
captured in situ in a microarray format at the time of assay. The microarrays are 
used to assay thousands of protein interactions simultaneously to discover 
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autoantibody biomarkers correlated to specific diseases and to detect antibodies 
to pathogens. To preserve protein function, assays using NAPPA are typically 
done within hours of expressing fresh proteins without ever allowing them to dry 
out. Unlike Ag produced from cells these proteins are freshly made and do not 
require the step of harvesting the protein from the organism. Certain devices, 
microreactors, utilize NAPPA to detect different Abs at high sensitivities [27].  
   NAPPA was utilized to assist in identifying AAb in both breast and ovarian 
cancer. These custom protein microarray technology NAPPA were generated by 
printing full-length complementary DNA (cDNAs) encoding the target proteins at 
each feature of the array. A capture antibody, protein cross linker and Bovine 
serum albumin (BSA) are co-printed with the cDNAs onto the surface of the 
array. The capture antibody recognizes a certain tag that would be fused onto the 
desired protein. Glutathione S-transferase (GST) is commonly used to tag the 
proteins and an anti-GST antibody is used as the capture antibody. Once the 
proteins transcribed and translated by a cell-free system they become 
immobilized (captured) in situ using epitope tags fused to the proteins. Sera are 
added, and bound IgG is detected by standard secondary reagents (Figure 5) 
[28]. 
A recent study used sera from ovarian cancer patients to detect AAbs. 5177 
candidate tumor antigens were expressed using NAPPA. Followed by adding 
sera from patients with serous ovarian cancer (34 cases/30 controls) and 
measured bound IgG. Of these, 741 antigens were selected and probed with an 
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independent set of ovarian cancer sera (n60 cases/60 controls). Twelve potential 
autoantigens were identified with sensitivities ranging from 13 to 22% at >93% 
specificity. These were retested using a Luminex bead array using 60 cases and 
60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. The top 
three AAb were tumor protein 53 (p53), protein tyrosine phosphatase receptor 
type A (PTPRA), and prostaglandin F receptor (PTGFR). The sensitivity of AAb 
to p53 was 53.3%, while the sensitivity of PTGFR was 16.7% and PTPRA was 
133% at a 93.3% specificity [29].  
 
Figure 5 NAPPA Displays the process of NAPPA, starting from creating the protein from 
the DNA template followed by the capture of the protein using and then primary and 
secondary Ab binding [31]. 
More research directed these methods in the study of Basal-like breast cancer 
(BLBC). BLBC is a rare aggressive subtype that has a lower chance to be 
detected through mammographic screening. Identification of circulating markers 
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associated with BLBC could have promise in detecting and managing this mortal 
disease. ~10,000 full-length human proteins were analyzed as potential antigens 
that can identify certain AAb markers (Largest proteomic screen using NAPAA). 
13 AAbs were identified against the following proteins: CTAG1B, CTAG2, TP53, 
RNF216, PPHLN1, PIP4K2C, ZBTB16, TAS2R8, WBP2NL, DOK2, PSRC1, 
MN1, TRIM21 that distinguished BLBC from controls with 33% sensitivity and 
98% specificity. It was assumed that some of these AAbs markers are related to 
the over expression of their mRNA/protein targets in the BLBC themselves [30]. 
This study serves as an excellent example of protein micro assays in detecting 
novel markers, AAbs, from a large pool of molecules. 
Conclusion 
Current projections and estimates show no decrease in the amount of deaths 
caused by cancer [32]. Multiple steps must be taken to address this issue. One of 
the most essential ones is to be capable of detecting tumors at early stages in 
order provide the proper treatment and increase survival rate. Also, a more 
comprehensive understanding of mechanisms and pathways regarding cancer 
molecules is required to be able to fully tackle the problem that cancer patients 
face.  For it has been illustrated through cancer associated retinopathy (CAR), an 
autoimmune response against retinal cells caused by tumors, that the reach of 
cancers goes beyond tumors and metastasis and the science community has 
much to learn [33-35]. Currently it seems that AAbs provide the most promising 
results in serving as a biomarker for cancer, with a higher sensitivity and 
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specificity than TAAs. Novel techniques and technologies such as RAPID 
ELISSAs and NAPPA provide a promising prospective for the field of protein 
microarrays [36].    
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APPENDIX 
 
Antibody: a large, Y-shaped protein produced mainly by plasma cells that is 
used by the immune system to identify and neutralize pathogens such as 
bacteria and viruses. 
Antigen: a molecule capable of inducing an immune response on the part of the 
host organism 
Autoantibodies: is an antibody that recognize and induce a immune response 
against self-cells.  
Immunoassays: is a biochemical test that measures the presence or 
concentration of a macromolecule or a small molecule in a solution through the 
use of an antibody.  
Proteome: The entire set of proteins that are expressed within a cell.   
Tumor associated antigen: is an antigen that is produced from tumor cells and 
is recognized by autoantibodies. 
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